Sionna Therapeutics, Inc. (SION) research
Sionna Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $4.91
- As of
Sionna Therapeutics, Inc. (SION): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
As of . Source: SEC EDGAR filings for SION. Method and limitations.
Share the SION intelligence card
See the full SION dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SION on one page. Preview it with sample data, then open it live with a free account.
Preview the SION dossierActive signals for SION
- highCONSENSUS_BUY
5 tracked funds increased SION this 2026Q2, institutional consensus
- highCONSENSUS_SELL
3 tracked funds reduced SION this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 64% of SION (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 80% of SION (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 86% of SION (2026Q2)
FREE, NO ACCOUNT
Every signal on SION, as it fires
You are seeing 5 of 15 signals recorded on SION since 2026-05-17.
The five above landed across 2 days. The other 10 were recorded on 3 other days. 8 of the 15 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SION (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP 829401108 · 2026Q2 | $140.6M | 0.40% | , |
| CITADEL ADVISORS LLCCUSIP 829401108 · 2026Q2 | $50.5M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 829401108 · 2026Q2 | $12.2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 829401108 · 2026Q2 | $4.5M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 829401108 · 2026Q2 | $2.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SION
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SION against its peers
SION's return on equity of -24.5% ranks in the 63rd percentile of 22 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | SION | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 25.4M | n/a | 21 |
| Gross margin | n/a | 58.3% | n/a | 5 |
| Operating margin | n/a | -203.1% | n/a | 20 |
| Net margin | n/a | -265.2% | n/a | 21 |
| Return on equity | -24.5% | -51.6% | 63 | 22 |
Peers (25): PRQR, LYEL, LCTX, MGNX, SLGL, ZNTL, KROS, RNAC, IVVD, BCYC, NAGE, CGEN, PLX, ANTX, PALI, CAMP, WHWK, IFRX, TRDA, ANIK, NWBO, XGN, ELDN, ALEC, STRO. Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (SION: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SION signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SIONand get the insider, 13F, options, and confluence read in one view.